Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Cycle 1~* Signed written informed consent~* Histologically or cytologically confirmed solid tumor malignancy.~* Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy will be permitted.~* Scheduled to receive at least 4 repeated consecutive cycles of the following highly emetogenic reference chemotherapies (HEC), alone or in combination with other chemotherapeutic agents on Day 1: cisplatin administered as a single IV dose of ≥ 70 mg/m2; cyclophosphamide ≥1500 mg/m2; carmustine (BCNU) \>250mg/m2; dacarbazine (DTIC); mechloretamine (nitrogen mustard)~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 .~* If a patient is female, she shall be of non-childbearing potential or of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test.~* Hematologic and metabolic status adequate for receiving an highly emetogenic regimen based on laboratory criteria (Total Neutrophils,Platelets, Bilirubin, Liver enzymes, Serum Creatinine or Creatinine Clearance)~* Able to read, understand, follow the study procedure and complete patient diary.~Cycles 2 to 4:~The following inclusion criteria must be checked prior to inclusion at each repeated cycle:~* Participation in the study during the next cycle of chemotherapy is considered appropriate by the Investigator and does not pose unwarranted risk to the patient.~* Scheduled to receive the same chemotherapy regimen as Cycle 1 or one of the reference chemotherapies as defined in Inclusion criterion 5 for Cycle 1.~* If a patient is female, she shall be of non--childbearing potential or of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test.~* Adequate hematologic and metabolic status according to the Investigator's opinion.~Exclusion Criteria:~Cycle 1~* Lactating woman.~* Active infection or uncontrolled disease except for malignancy that may pose unwarranted risks in administering the study drugs to the patient.~* Current use of illicit drugs or current evidence of alcohol abuse.~* Scheduled to receive moderately or highly emetogenic chemotherapies from Day 2 to Day 5.~* Received or is scheduled to receive radiation therapy to the abdomen or the pelvis within 1 week prior to the start of the reference chemotherapy administration on Day 1 or between Days 1 to 5.~* Any vomiting, retching, or nausea (grade ≥ 1 as defined by National Cancer Institute) within 24 hours prior to the start of the reference chemotherapy administration on Day 1.~* Symptomatic primary or metastatic CNS malignancy.~* Known hypersensitivity or contraindication to 5-HT3 receptor antagonists, to dexamethasone or to NK-1 receptor antagonists.~* Known contraindication to the IV administration of 50 mL 5% glucose solution.~* Previously received an NK-1 receptor antagonist.~* Participation in a previous clinical trial involving IV pro-netupitant or oral netupitant administered alone or in combination with palonosetron.~* Any investigational drugs (other than those given in this study) taken within 4 weeks prior to Day 1, and/or is scheduled to receive any investigational drug during the present study.~* Systemic corticosteroid therapy at any dose within 72 hours prior to the start of reference chemotherapy administration on Day 1. Topical and inhaled corticosteroids are permitted.~* Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy.~* Scheduled to receive any strong or moderate inhibitor of CYP3A4 or its intake within 1 week prior to Day 1.~* Scheduled to receive any of the following CYP3A4 substrates within 1 week prior to Day 1: terfenadine, cisapride, astemizole, pimozide.~* Received within 4 weeks prior to Day 1 or scheduled to receive any CYP3A4 inducer.~* Any medication with known or potential antiemetic activity within 24 hours prior to the start of reference chemotherapy administration on Day 1 of Cycle 1, including but not limited to 5-HT3 receptor antagonists and NK-1 receptor antagonists~* History or predisposition to cardiac conduction abnormalities, except for incomplete right bundle branch block~* History of Torsade de Point or known history of risk factors for Torsade de Point (heart failure, hypokalemia, family history of Long QT Syndrome).~* Severe cardiovascular diseases diagnosed within 3 months prior to Day 1 of first cycle, including myocardial infarction, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III-IV, and severe uncontrolled arterial hypertension.~* Any illness or condition that, in the opinion of the Investigator, may confound the results of the study or pose unwarranted risks in administering the investigational product to the patient.~* Concurrent medical condition that would preclude administration of dexamethasone such as systemic fungal infection or uncontrolled diabetes.~Cycles 2 to 4:~The following exclusion criteria must be checked prior to inclusion in each repeated cycle:~* Lactating woman.~* Active infection or uncontrolled disease except for malignancy that may pose unwarranted risks in administering the study drugs to the patient.~* Started any of the restricted medications.~* Any vomiting, retching, or nausea (grade ≥ 1 as defined by National Cancer Institute) within 24 hours prior to the start of reference chemotherapy administration on Day 1.~* Received or is scheduled to receive radiation therapy to the abdomen or the pelvis within 1 week prior to the start of the reference chemotherapy administration on Day 1 or between Days 1 to 5.~* Symptomatic primary or metastatic CNS malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pro-netupitant/Palonosetron plus Dexamethasone (Type: EXPERIMENTAL): Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
- Netupitant/Palonosetron plus Dexamethasone (Type: ACTIVE_COMPARATOR): Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).